

About Us

BioncoTech is a biotech company engaged in the development of RNA therapies to treat numerous aggressive types of cancer. Our lead compound is BO-110, a dsRNA nano-complex that possesses a unique mechanism of action. It elicits cell death by addressing three different pathways (**immunomodulation, apoptosis and autophagy**). Furthermore, we have set up a screening method that enables identification of new compounds that follow the same mode of action and hence are suitable to treat cancer in this unique fashion.

We are located at Valencia's Scientific Park and have reputed researchers in the field of oncology along with experts in business and company development. Our team comprises PhDs, MBAs, MDs and highly skilled clinicians.



Technology Platform

BioncoTech carries out the following developments:

- 🕒 **BO-110** through pre-clinical and clinical trials for the treatment of melanoma, pancreatic cancer, bladder cancer and hepatic cancer.
- 🕒 **Pipeline completion** with reformulations of BO-110, new molecular entities and a delivery strategy for these compounds.
- 🕒 **Proprietary assay** method by means of high content screening to identify new compounds that follow the same mode of action to that of BO-110 and therefore represents new therapeutic opportunities in cancer.
- 🕒 **Test combinations** of existing drugs in the market with new ones and check potential improvements in their clinical performance.

Advantages

- 🕒 **Proof of principle** in animal models that shows a promising therapeutic efficacy in multiple human tumors.
- 🕒 **Unique mechanism of action** that differs from standard current therapies.
- 🕒 **No apparent side effects or toxicity** in pre-clinical cancer models.
- 🕒 **Selectivity** for tumor cells.
- 🕒 **Strong IP** with no FTO issues. Up to 16 years of exclusivity after launch based on data exclusivity, patent protection, orphan status and extension possibilities.

Commercial Opportunity

Worldwide data on main indications are found below:

Target Tumors	Frequency (100,000)	Cases/year	Deaths
Melanoma	2,7	106,000	33,000
Pancreas cancer	10	170,000	168,000
Bladder cancer	4,2	269,000	115,000
Hepatic carcinoma	7,7	560,000 (half China)	600,000

There are the following strong medical needs:

- 🕒 **High mortality.**
- 🕒 **No effective treatments.**
- 🕒 **High side effects.**
- 🕒 **Devastating social impact.**

Market attractiveness:

- 🕒 **Multi-billion expenses** in medical and palliative case.
- 🕒 **Orphan disease status** (advantages for implementation and IP protection).

Current Status

The first round of financing has been successfully completed. BioncoTech has been granted research loans and funding from public sources. Pre-clinical regulatory trials are currently ongoing.

Financial Opportunity

- 🕒 **Funding need estimation:** 5M€ to complete IND filing, phase I clinical trials and start phase II in the next 3 years.
- 🕒 **20% stake:** Genoma España offers any interested investor willing to capitalize its share and strategically contribute to BioncoTech's technology development and business.

Contact:

Damià Tormo, PhD, MBM
CEO
+34 663 332 911
damia.tormo@bioncotech.com
<http://www.bioncotech.com/>



Contact:

Juan Pedro Rodríguez Serrate
Project Manager
+34 914 491 250 EXT 043
jp.rodriguez@gen-es.org
<http://www.gen-es.org/>

